Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | PTPRB | P23467 | 1/20 | 0.57 |
| ▸ | CDC25A | P30304 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
| ▸ | PTEN | P60484 | 1/20 | 0.57 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25168667 | 0.89 | SMN1; SMN2 (0.63) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL30805270 | 0.87 | MAPT (0.62) | HDAC3MAPK1ADRA1AHDAC4SLC6A3 | |
| SCHEMBL8661713 | 0.86 | MAPT (0.66) | HDAC3MAPK1ADRA1AHDAC4SLC6A3 | |
| SCHEMBL10332840 | 0.86 | MAPT (0.66) | HDAC3MAPK1ADRA1AHDAC4SLC6A3 | |
| SCHEMBL70271 | 0.86 | KEAP1 (0.74) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| Hydrochloric Acid SCHEMBL10982620 | 0.84 | KEAP1 (0.71) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL28184245 | 0.83 | CYP2D6 (0.51) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL22046251 | 0.83 | TRPV1 (0.45) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| Phenyl Propionic Acid SCHEMBL8043510 | 0.83 | TDP1 (0.53) | KEAP1FFAR1FFAR4 | |
| SCHEMBL8614478 | 0.81 | KEAP1 (0.67) | KEAP1PTPRBCDC25ACDC25BPTEN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4252719-A | REMOVAL OF A TERTIARY HYDROGEN FROM A 5-A-STEROID BY CHLORINATING THE STEROID BEING FIRST ESTERIFIED BY AN IODOARYL-CONTAINING ESTERIFICATION AGENT | RESEARCH CORPORATION (US) | 1981-02-24 | — | — | US | claimed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025088200-A2 | ACID PHOSPHATASE 3 LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024259310-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| CN-116194155-A | Urea-based ligands targeting PSMA for prostate cancer radiotherapy and imaging | 哥本哈根大学 | 2023-05-30 | — | — | CN | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | disclosed |
| US-10512700-B2 | Radiohalide-labeled targeted diagnostics and therapeutics | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-12-24 | — | — | US | disclosed |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20040167188-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; | ABBOTT LABORATORIES | 2004-08-26 | — | — | US | disclosed |
| US-20040162331-A1 | Pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1386913-A1 | PYRROLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| US-4925649-A | Radioiodinated diacylglycerol analogues and methods of use | THE UNIVERSITY OF MICHIGAN (US) | 1990-05-15 | — | — | US | disclosed |
| US-4925649-A | Radioiodinated diacylglycerol analogues and methods of use | THE UNIVERSITY OF MICHIGAN (US) | 1990-05-15 | — | — | US | disclosed |
| US-4252719-A | REMOVAL OF A TERTIARY HYDROGEN FROM A 5-A-STEROID BY CHLORINATING THE STEROID BEING FIRST ESTERIFIED BY AN IODOARYL-CONTAINING ESTERIFICATION AGENT | RESEARCH CORPORATION (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | KEAP1 673/4885PTPRB 1542/4885CDC25A 2613/4885 |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | KEAP1 673/4885PTPRB 1542/4885CDC25A 2613/4885 |
| US-20040162331-A1 | Pyrrole derivative | SLC5A1, GLP1R, SLC5A2 | KEAP1 3207/4885PTPRB 1543/4885CDC25A 2165/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | KEAP1 673/4885PTPRB 1542/4885CDC25A 2613/4885 |
| US-20040167188-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; | G6PC1, PPP1R1B, PPP1R7 | KEAP1 1974/4885PTPRB 36/4885CDC25A 217/4885 |
| US-10512700-B2 | Radiohalide-labeled targeted diagnostics and therapeutics | PARP11, PARP1, PARP12 | KEAP1 882/4885PTPRB 4728/4885CDC25A 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.